Knut Sverre Skurdal Andresen

Knut Sverre Skurdal Andresen

Partner, Oslo Download CV Download vCard

Knut Sverre is working with litigation in the ordinary courts and with dispute resolution in international and national arbitration. He specialises in IP dispute resolution, and works particularly with patent disputes concerning pharmaceutical, fishing, transportation and offshore technology, as well as trademark, copyright, unfair competition and marketing law disputes, and IT disputes. Knut Sverre also advises clients in cutting edge technology development projects and technology/IP M&A, and is considered a preferred strategic advisor in commercial IP and licensing matters. He has been involved in some of the most significant patent disputes before Norwegian courts in recent time. He also has broad experience from disputes concerning various commercial law matters.

Knut Sverre appears regularly as a seminar speaker and lecturer on various IP and civil procedural issues. He is author of The Legal 500 Intellectual Property Comparative Legal Guide Norway, Chambers Patent Litigation Practice for Norway and co-author of the online annotated Norwegian Civil Procedure Act.

In 2020, Knut Sverre wrote the Chambers Global Practice Guide: Patent Litigation Norway. Read the publication here. Also in 2020, Knut Sverre wrote the Legal 500 Intellectual Property Comparative Legal Guide Norway. Read the publication here.

Practice areas

Personable, impeccable, a superb advocate, and a pleasure to work with." Legal 500

About Knut Sverre


  • Attorney in charge of several patent validity and infringement cases
  • Attorney in charge of several trademark law, unfair competition law and marketing law cases
  • Attorney in charge of SCC arbitrations concerning i.a. product design and offshore technology
  • Attorney in charge for more than 150 arbitration and litigation cases concerning IP, licencing, contract law and agency law
  • Attorney in charge of several cutting edge technology development projects, e.g. concerning MedTech, AI technology, autonomous driving, and transportation infrastructure


  • 2021

    Next Generation Partners, Recommended and Other key lawyer - Legal 500

  • 2020

    Recommended - Legal 500: 'Knut Sverre Skurdal Andersen is analytical and provides well thought through advice. As a client, you can trust that he always has taken the full perspective and next step into account.‘

  • 2020

    Knut Sverre Skurdal Andresen "thrives when untangling knotty disputes in the pharmaceutical sector", WTR 1000

  • 2019

    “Rising Star” - Managing Intellectual Property IP Stars

  • 2018

    “Rising Star” - Managing Intellectual Property IP Stars


  • 2008

    Master of Law, University of Oslo

  • 2001

    Cambridge Syndicate Examination in Business Leadership, University of Cambridge


  • 2020

    Chambers Global Practice Guide: Patent Litigation Norway

  • 2020

    The Legal 500 Intellectual Property Comparative Legal Guide Norway

  • 2019

    Gyldendal Rettsdata, Commentary to the Norwegian Civil Procedure Act chapters 10, 20, 29, 30 and 31

  • 2009

    Obiter dicta as a source of law - a question of the role of the Courts of Justice. Changes in the Norwegian Supreme Court's argumentation in the time of internationalisation? Centre for European Law

  • 2009

    EuroRett nr. 1 2008 – nr. 1. 2009, Centre for European Law/Lovdata


  • Attorney in charge:Acted for Merck Sharp & Dohme in a multi-jurisdictional pharmaceutical patent and SPC infringement case concerning a pharmaceutical combination product comprising ezetimibe and simvastatin
  • Attorney in charge:Acted for one of Norway's largest suppliers of pharmaceuticals and health-related products in a litigation concerning purchase of shares in an independent pharmacy
  • Attorney in charge:Acted for a Norwegian client concerning biotechnology before the ordinary courts and The European Court of Human Rights
  • Attorney in charge:Acted for Norwegian company in several matters, i.a. transfer and novation of an infrastructure agreement worth NOK 10 billion, execution and implementation of the railroad reform and procurement of new rolling stock for the Norwegian railroads
  • Co-counsel:Acted for Gilead in Norway’s most significant pharmaceutical patent case, concerning validity of patents for treatment of hepatitis C with sofosbuvir